Gebremedhin Solomon Hailu

Dr. Gebremedhin Solomon Hailu

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2016 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
Vincenzo CarafaVincenzo Carafa
Vincenzo Carafa
DRDante Rotili
Dante Rotili
MFMariantonietta Forgione
Mariantonietta Forgione
FCFrancesca Cuomo
Francesca Cuomo
ESEnrica Serretiello
Enrica Serretiello
Lucia AltucciLucia Altucci
Lucia Altucci
Sirtuins are NAD+-dependent histone deacetylases regulating important metabolic pathways in prokaryotes and eukaryotes and are involved in many biological processes such as cell survival, senescence, proliferation, apoptosis, DNA repair, cell metabolism, and caloric restriction. The seven members of this family of enzymes are considered potential targets for the treatment of human pathologies including neurodegenerative diseases, cardiovascular diseases, and cancer. Furthermore, recent interest focusing on sirtuin modulators as epigenetic players in the regulation of fundamental biological pathways has prompted increased efforts to discover new small molecules able to modify sirtuin activity. Here, we review the role, mechanism of action, and biological function of the seven sirtuins, as well as their inhibitors and activators.

14 March 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SMSébastien Moniot
Sébastien Moniot
MFMariantonietta Forgione
Mariantonietta Forgione
ALAlessia Lucidi
Alessia Lucidi
GHGebremedhin Solomon Hailu
Gebremedhin Solomon Hailu
ANAngela Nebbioso
Angela Nebbioso
DRDante Rotili
Dante Rotili

15 March 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GHGebremedhin Solomon Hailu
Gebremedhin Solomon Hailu
DRDina Robaa
Dina Robaa
MFMariantonietta Forgione
Mariantonietta Forgione
Wolfgang SipplWolfgang Sippl
Wolfgang Sippl
DRDante Rotili
Dante Rotili
AMAntonello Mai
Antonello Mai

27 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TETadele Eticha
Tadele Eticha
ATAmha Teklu
Amha Teklu
DADagim Ali
Dagim Ali
GHGebremedhin Solomon Hailu
Gebremedhin Solomon Hailu
AAAdissu Alemayehu
Adissu Alemayehu
Non-adherence to antipsychotic medication has a negative impact on the course of illness resulting in increased risk of relapse, rehospitalization and suicide, and increased costs to healthcare systems. The objective of this study was to investigate factors associated with medication adherence among patients with schizophrenia at Ayder Referral Hospital and Mekelle Hospital in Mekelle, Tigray region, Northern Ethiopia. The study was a cross-sectional survey in which sociodemographic characteristics, drug attitudes, insight and side effects were measured and explored in terms of their relationship with medication adherence. A structured questionnaire as a data collection tool was used. Data were analyzed with the help of SPSS Version 20.0. A total of 393 patients participated, 26.5% were non-adherent to their antipsychotic medication. The factors significantly associated with better adherence were positive treatment attitudes (AOR = 1.40, 95% CI: 1.26, 1.55), fewer side effects (AOR = 0.97, 95% CI: 0.94, 0.99), awareness of illness (AOR = 1.44, 95% CI: 1.12, 1.85) and the ability to relabel symptoms (AOR = 1.57, 95% CI: 1.19, 2.07). However, khat chewers (AOR = 0.24, 95% CI: 0.09, 0.68), being illiterate (AOR = 0.13, 95% CI: 0.03, 0.47) and older age group (AOR = 0.03, 95% CI: 0.01, 0.16) were associated with less medication adherence. A high prevalence of medication non-adherence was found among patients with schizophrenia. Intervention strategies focused on educating the patients to better understand the illness, medications and their potential side effects might be useful in improving adherence to antipsychotic medication treatment.

7 December 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MNMaxim B. Nawrozkij
Maxim B. Nawrozkij
MFMariantonietta Forgione
Mariantonietta Forgione
AYAlexandre S. Yablokov
Alexandre S. Yablokov
ALAlessia Lucidi
Alessia Lucidi
DTDaniela Tomaselli
Daniela Tomaselli
DRDante Rotili
Dante Rotili

31 May 2013 in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
Verified
Journal Article
Closed access
PDF file
GHGebremedhin Solomon Hailu
Gebremedhin Solomon Hailu
GGGirma Belachew Gutema
Girma Belachew Gutema
HHHailemichael Zeru Hishe
Hailemichael Zeru Hishe
YAYimer Said Ali
Yimer Said Ali
AAAdissu Alemayehu Asfaw
Adissu Alemayehu Asfaw
The availability of multisource generic brands of amoxicillin in the market today places health professionals and patients in a difficult situation about the choice of a suitable product among numerous generic brands. The purpose of this study was to estimate the bioequivalence of amoxicillin capsules marketed in Ethiopia using in vitro tests in order to determine their interchangeability. The in vitro dissolution study was carried out on the six brands of amoxicillin capsules according to USP guidelines. To compare the dissolution profiles, a difference factor (f1), similarity factor (f2), dissolution efficiency (DE) and statistical methods were employed. Results have shown significant differences in the dissolution profiles of the brands based on the statistical analysis (p<0.0001). Pair-wise comparisons using Dunnett’s test indicated that the innovator brand has a significantly faster dissolution than the generic brands, except brand D. According to f1, f2 and DE calculations, only brand D was found to have similar dissolution profile with the innovator. Based on the in vitro studies, only brand D may be considered bioequivalent and interchangeable, while the other brands may not be considered bioequivalent and interchangeable with the innovator brand. This research highlights among other things the need for constant monitoring and surveillance on the marketed drugs by regulatory bodies to ascertain bioequivalence and quality medicines, especially for drugs like amoxicillin for which there exists evidence of non-bioequivalence from different firms, resulting in efficacy issues.